Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Keros Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 10K | May 30, 2024 | Direct | ||
Eloxx Pharmaceuticals, Inc. | Director | Stock Options (Right to Buy) | 2.86K | Jan 30, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KROS | Keros Therapeutics, Inc. | May 30, 2024 | 1 | $0 | 4 | Jun 3, 2024 | Director, 10%+ Owner |
KROS | Keros Therapeutics, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
ELOX | Eloxx Pharmaceuticals, Inc. | Jan 30, 2023 | 1 | $0 | 4 | Jan 31, 2023 | Director |
KROS | Keros Therapeutics, Inc. | Nov 29, 2022 | 6 | -$1 | 4 | Nov 30, 2022 | Director, 10%+ Owner |
ELOX | Eloxx Pharmaceuticals, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director |
KROS | Keros Therapeutics, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director, 10%+ Owner |
KROS | Keros Therapeutics, Inc. | Jun 1, 2021 | 1 | $0 | 4 | Jun 3, 2021 | Director, 10%+ Owner |
ELOX | Eloxx Pharmaceuticals, Inc. | May 19, 2021 | 1 | $0 | 4 | May 20, 2021 | Director |
ELOX | Eloxx Pharmaceuticals, Inc. | May 13, 2021 | 4 | $8M | 4 | May 17, 2021 | Director |
KROS | Keros Therapeutics, Inc. | Apr 7, 2020 | 0 | $0 | 3/A | Nov 30, 2022 | Director, 10%+ Owner |